AstraZeneca
rare disease | AstraZeneca
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
9 of 49
Related slides by other companies
Equillium
Investor Presentation
December 2023
clinically validated in severe dermatological disease | Equillium
Ocuphire Pharma
Results
October 2022
oral treatments in clinical development | Ocuphire Pharma
DICE Therapeutics
Investor Presentation
March 2023
dice pipeline overview | DICE Therapeutics
AN2 Therapeutics
IPO
March 2022
a day phase dose ranging study of oral supports once daily dose for patients with treatment refractory mac lung disease phase design and results mere male placebo generally well tolerated no serious adverse events no severe aes no deaths linear and predictable results support further clinical development of in lung disease data from and other clinical studies combined into population model results used in combination with preclinical data to determine oral dosage for study phase pivotal trial once daily dose achieved high probability of target attainment for treatment of mac lung disease and was well tolerated an therapeutics | AN2 Therapeutics
Other recent decks by AstraZeneca
See all presentations (31 decks)
Results
February 2025
Results
November 2024
Results
November 2024
Investor Event
September 2024
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights